Solventum Corporation
NYSE:SOLVMedical - Care Facilities
-$2.00 today
- Market cap
- $14.70B
- Beta
- 0.75
- P/E (TTM)
- 9.1
- EPS (TTM)
- $8.22
Volume 0.76M
Average 1.70M
SOLV Other Investing Activities
Investing cash flows not reported separately.
Solventum CorporationNYSE: SOLV
Other Investing Activities · Q2 FY2026 · quarter ended Jun 2026
Other investing activities turns negative
Q2 FY2026 other investing activities was -$4M, compared with $0 a year earlier. Trailing-twelve-month other investing activities was $3.86B.
Context
- Other investing activities amounted to 46.5% of revenue in FY2025, up 46.5 pp from a year earlier.
- Other investing activities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other investing activities holds near -$4M or moves back toward the trailing-twelve-month quarterly average of $965M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Investing Activities history
USD · from the cash flow
- Latest · FY2025
- 3.87B USD
- Year-over-year change
- —
| Period | Period end | Other Investing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.87B | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | +100.0% |
| FY2022 | 2022-12-31 | (2M) | -100.0% |
| FY2021 | 2021-12-31 | (1M) | — |
Other Investing Activities vs competitors
How SOLV compares with its peers on the latest reported figures
- SOLV's LTM Jun 2026 other investing activities of $3.86B is the largest of the 10 companies compared; the peer median is $58M.
- Its year-over-year change of +77300.0% is the highest of 9, against a peer median of -67.5%.
- Other investing activities amounts to 46.5% of revenue for SOLV, versus a peer median of 0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.86B | +77300.0% | — | 46.5% | |
| LTM Jul 2026 | $266.2M | -214.7% | — | 6.3% | |
| LTM Jun 2026 | $213.67M | -209.6% | — | 9.9% | |
| LTM Jun 2026 | $181M | -105.6% | — | 1.6% | |
| LTM Sep 2026 | $113M | -131.6% | -4.2% | 0.6% | |
| LTM Jun 2026 | $58M | +48.7% | -23.1% | 0.4% | |
| LTM Sep 2026 | $38.55M | -29.3% | +63.3% | 2.4% | |
| LTM Mar 2026 | $4M | -20.0% | -20.6% | 0.1% | |
| LTM Oct 2026 | $3.8M | +162.3% | -25.6% | 0.1% | |
| LTM Mar 2026 | $310K | — | — | 0.8% | |
| Peer median (excluding SOLV) | $58M | -67.5% | -20.6% | 0.8% | |
Competitors are the stored peer set for SOLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.46B | 1.34B | 1.35B | 479M | 1.56B |
| Depreciation & Amortization | 597M | 578M | 561M | 555M | 489M |
| Deferred Income Tax | (34M) | (141M) | (142M) | (155M) | (120M) |
| Stock-Based Compensation | 38M | 37M | 39M | 112M | 161M |
| Change in Working Capital | 67M | (202M) | 126M | 160M | (119M) |
| Accounts Receivables | (1M) | (32M) | (129M) | 276M | 78M |
| Inventory | (136M) | (82M) | 23M | (132M) | (139M) |
| Accounts Payables | 68M | 25M | 105M | 266M | 104M |
| Other Working Capital | 136M | (113M) | 127M | (250M) | (162M) |
| Other Non-Cash Items | 74M | 64M | (15M) | 34M | (1.6B) |
| Operating Cash Flow | 2.2B | 1.68B | 1.92B | 1.19B | 369M |
| Capital Expenditures | (277M) | (251M) | (290M) | (380M) | (379M) |
| Acquisitions (Net) | 0 | 0 | 60M | 0 | (696M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (1M) | (2M) | 0 | 0 | 3.87B |
| Investing Cash Flow | (278M) | (253M) | (230M) | (380M) | 2.8B |
| Debt Repayment | 0 | 0 | 0 | 8B | (3.07B) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.96B) | (1.46B) | (1.55B) | (8.24B) | 13M |
| Financing Cash Flow | (1.96B) | (1.46B) | (1.55B) | (240M) | (3.06B) |
| Effect of Forex Changes | 3M | 4M | 0 | 3M | 7M |
| Net Change in Cash | (33M) | (30M) | 133M | 568M | 116M |
| Free Cash Flow | 1.93B | 1.43B | 1.63B | 805M | (10M) |
Solventum Corporation
NYSE:SOLV
Intrinsic Alpha fair value
Locked
Current Price
$86.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.